Background: Ductal carcinoma in situ (DCIS) is a non-invasive breast malignancy commonly detected through screening programs such as Breast Screen Australia. Surgical management with or without adjuvant therapy yields excellent survival outcomes; however, recurrence and new breast events remain clinically relevant. With rising breast cancer incidence and increasing survivorship, tertiary breast clinics face growing capacity pressures. Patients treated for primary DCIS represent a potentially lower-risk cohort who may be suitable for earlier transition to community-based surveillance. Aim: To evaluate post-surgical events during five years of follow-up following treatment for primary DCIS at the Royal Brisbane & Woman’s Hospital (RBWH), and to assess whether the current five-year specialist surveillance period is justified. Methods: A retrospective cohort study was conducted of patients who underwent surgical treatment for DCIS at RBWH Hospital between 1 January 2015 and 31 December 2019, with a minimum of five years’ follow-up. Patients with concurrent invasive carcinoma at diagnosis or incomplete surveillance data were excluded. Data was extracted from histopathology reports, electronic medical records, and multidisciplinary meeting summaries. Collected variables included patient demographics, tumour histopathology, treatment details, surveillance findings, and clinical outcomes. The primary outcome was the incidence of recurrent DCIS, new invasive breast carcinoma, or B3 lesions during follow-up. Secondary outcomes included the proportion of patients requiring additional diagnostic imaging or biopsy. Results Data collection and analysis currently underway. We look forward to presenting the results Conclusion: This study provides Australian data on outcomes following treatment for DCIS. Findings aim to inform risk-stratified follow-up pathways and may support earlier transition of selected patients to community-based surveillance while maintaining patient safety and optimising tertiary service capacity.